# Colorectal Adjuvant FOLFOX (a7) - HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide v0.1.0

* [**Table of Contents**](toc.md)
* [**Artifacts Summary**](artifacts.md)
* **Colorectal Adjuvant FOLFOX (a7)**

## PlanDefinition: Colorectal Adjuvant FOLFOX (a7) 

| | |
| :--- | :--- |
| *Official URL*:http://hl7.org.nz/fhir/ig/cca/PlanDefinition/ColoRectal | *Version*:0.1.0 |
| Active as of 2020-06-29 | *Computable Name*: |
| **Usage:**Clinical Focus: Colorectal cancer | |

 
A drug treatment regimen for Colorectal cancer. Plan is still under review. 

Plan for ColoRectal cancer. There is a single cycle with 2 drug administrations



## Resource Content

```json
{
  "resourceType" : "PlanDefinition",
  "id" : "ColoRectal",
  "meta" : {
    "profile" : ["http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"]
  },
  "contained" : [{
    "resourceType" : "ActivityDefinition",
    "id" : "ActTragacanth",
    "meta" : {
      "profile" : ["http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"]
    },
    "text" : {
      "status" : "additional",
      "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Tragacanth administration, 3mg over 3 hours by continuous IV infusion</div>"
    },
    "status" : "draft",
    "productCodeableConcept" : {
      "coding" : [{
        "system" : "https://nzulm.org.nz/nzmt",
        "code" : "10711851000116105",
        "display" : "Tragacanth"
      }]
    },
    "dosage" : [{
      "text" : "3 mg over 3 hours by IV infusion",
      "route" : {
        "coding" : [{
          "system" : "http://snomed.info/sct",
          "code" : "180177004",
          "display" : "continuous intravenous infusion"
        }]
      },
      "doseAndRate" : [{
        "doseQuantity" : {
          "value" : 3,
          "system" : "http://unitsofmeasure.org",
          "code" : "mg"
        },
        "rateQuantity" : {
          "value" : 3,
          "system" : "http://unitsofmeasure.org",
          "code" : "h"
        }
      }]
    }]
  }],
  "extension" : [{
    "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
    "valueMarkdown" : "Only for women"
  },
  {
    "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-disclaimer",
    "valueMarkdown" : "Developed with the best of intentions."
  },
  {
    "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-regimen-type",
    "valueCodeableConcept" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "dummy"
      }],
      "text" : "Folfox"
    }
  },
  {
    "extension" : [{
      "url" : "factor",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "http://snomed.info/sct",
          "code" : "TOUPDATE-SUPPORT4",
          "display" : "Diarrhoea risk"
        }]
      }
    },
    {
      "url" : "value",
      "valueCodeableConcept" : {
        "text" : "low"
      }
    }],
    "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
  },
  {
    "extension" : [{
      "url" : "factor",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "http://snomed.info/sct",
          "code" : "TOUPDATE-SUPPORT8",
          "display" : "AntiFungal Prophylaxis"
        }]
      }
    },
    {
      "url" : "value",
      "valueCodeableConcept" : {
        "text" : "low"
      }
    }],
    "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
  },
  {
    "extension" : [{
      "url" : "factor",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "http://snomed.info/sct",
          "code" : "TOUPDATE-SUPPORT2",
          "display" : "Hypersensitivity / Infusion related reaction ris"
        }]
      }
    },
    {
      "url" : "value",
      "valueCodeableConcept" : {
        "text" : "low"
      }
    }],
    "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-support-factor"
  }],
  "url" : "http://hl7.org.nz/fhir/ig/cca/PlanDefinition/ColoRectal",
  "version" : "0.1.0",
  "title" : "Colorectal Adjuvant FOLFOX (a7)",
  "type" : {
    "coding" : [{
      "system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
      "code" : "clinical-protocol"
    }]
  },
  "status" : "active",
  "_status" : {
    "extension" : [{
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-additional-plan-status",
      "valueCode" : "review"
    }]
  },
  "experimental" : false,
  "date" : "2020-06-29T20:14:18.417+12:00",
  "publisher" : "Te Aho o Te Kahu, Cancer Control Agency",
  "description" : "A drug treatment regimen for Colorectal cancer. Plan is still under review.",
  "useContext" : [{
    "code" : {
      "system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
      "code" : "focus"
    },
    "valueCodeableConcept" : {
      "coding" : [{
        "system" : "http://snomed.info/sct",
        "code" : "781382000",
        "display" : "Colorectal cancer"
      }]
    }
  }],
  "relatedArtifact" : [{
    "type" : "citation",
    "display" : "test",
    "url" : "http://www.ncbi.nlm.nih.gov/pubmed/23434",
    "document" : {
      "url" : "http://www.ncbi.nlm.nih.gov/pubmed/23434"
    }
  },
  {
    "type" : "citation",
    "display" : "test2",
    "url" : "http://www.ncbi.nlm.nih.gov/pubmed/34324",
    "document" : {
      "url" : "http://www.ncbi.nlm.nih.gov/pubmed/34324"
    }
  }],
  "action" : [{
    "extension" : [{
      "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
      "valueMarkdown" : "Ensure not pregnant before starting"
    }],
    "title" : "This is the only cycle in the regimen.",
    "description" : "Administration of Cabergoline and Tragacanth. Cycle length 14 days",
    "timingTiming" : {
      "repeat" : {
        "count" : 1,
        "duration" : 14,
        "durationUnit" : "d"
      }
    },
    "selectionBehavior" : "all",
    "action" : [{
      "extension" : [{
        "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-plan-instructions",
        "valueMarkdown" : "Keep a close eye for side effects"
      },
      {
        "extension" : [{
          "url" : "day",
          "valueInteger" : 1
        },
        {
          "url" : "instructions",
          "valueString" : "Specific instructions for the day 1 administration"
        }],
        "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
      },
      {
        "extension" : [{
          "url" : "day",
          "valueInteger" : 4
        },
        {
          "url" : "instructions",
          "valueString" : "Specific instructions for the day 4 administration"
        }],
        "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
      }],
      "description" : "2mg of Cabergoline daily on days 1 and 4 by IV Infusion over 20 minutes",
      "definitionCanonical" : "#act-cabergoline"
    },
    {
      "extension" : [{
        "extension" : [{
          "url" : "day",
          "valueInteger" : 2
        },
        {
          "url" : "instructions",
          "valueString" : "Specific instructions for the day 2 administration"
        }],
        "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
      },
      {
        "extension" : [{
          "url" : "day",
          "valueInteger" : 3
        },
        {
          "url" : "instructions",
          "valueString" : "Specific instructions for the day 3 administration"
        }],
        "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
      },
      {
        "extension" : [{
          "url" : "day",
          "valueInteger" : 4
        },
        {
          "url" : "instructions",
          "valueString" : "Specific instructions for the day 4 administration"
        }],
        "url" : "http://hl7.org.nz/fhir/StructureDefinition/sact-timing-of-days"
      }],
      "description" : "3mg of Tragacanth daily on days 2,3 and 4 by IV Infusion over 3 hours",
      "definitionCanonical" : "#act-tragacanth"
    }]
  }]
}

```
